Saroglitazar is a dual PPAR agonist, currently approved in India for the treatment of diabetic dyslipidemia (hypertriglyceridemia in type 2 diabetes). It improves insulin sensitivity and lipid abnormalities (TG and non-HDL-C). It improves glycemic control. Preclinical trials - improves multiple markers of insulin resistance and NAFLD/NASH. Post-marketing clinical data - improvement in liver enzymes, liver fat content and glycemic parameters. It lowers TGs and addresses abnormal fat distribution in HIV lipodystrophy.